Flex Pharma has appointed William McVicar as its new president of research and development, in a role that will focus on advancing clinical trials in MS, ALS and Charcot-Marie-Tooth.
McVicar has 30 years of clinical development experience, most recently serving at Inotek in various roles such as executive VP of pharmaceutical development, chief scientific officer and president.
He said: “It is my great pleasure to be joining the Flex team that is applying the scientific advances of a Novel laureate to improving the lives of patients living with debilitating neurological diseases.
“In partnership with CMO Tom Wessel, my former Sepracor colleague, we are poised to execute on our US phase II development plans.”
Prior to his time at Inotek, McVicar has held roles in several pharmaceutical companies such as Sepracor, Sandoz, Novartis and Rhone Poulenc Rorer.
Christoph Westphal, CEO at Flex Pharma, said: “Bill has an impressive track record of multiple drug approvals based upon his operational excellence and execution.
“With their successful partnership from their time at Sepracor, Bill and our CMO, Dr Tom Wessel, are a great team to rapidly advance our phase II clinical trials in MS, ALS and Charcot-Marie-Tooth with FLX-787 which will be amongst the most advanced clinical programs in ALS and CMT.”